Samuel A. Jacobs

5.1k citations

143 papers · 2.9k indexed · h-index 25

Impact in

Oncology top 2%
- HER2/EGFR in Cancer Research
- Colorectal Cancer Treatments and Studies
- Cancer Treatment and Pharmacology
- Viral-associated cancers and disorders
Pathology and Forensic Medicine top 2%
- Lymphoma Diagnosis and Treatment

Papers in

Oncology 92
- Colorectal Cancer Treatments and Studies 56
- Cancer Treatment and Pharmacology 30
- HER2/EGFR in Cancer Research 18
- Colorectal Cancer Surgical Treatments 14
Pathology and Forensic Medicine 52
- Lymphoma Diagnosis and Treatment 29
- Genetic factors in colorectal cancer 21

Co-authors: Ronald G. Stoller Bruce A. Chabner D G Johns Kenneth R. Hande Steven A. Rosenberg Norman Wolmark Steven H. Swerdlow K. H. Meyer zum Büschenfelde
Journals: Journal of Clinical Oncology (60 papers)Cancer Research (7 papers)Blood (6 papers)Clinical Breast Cancer (3 papers)Cancer Chemotherapy and Pharmacology (3 papers)
Partner nations: United States Canada Belgium

In The Last Decade

Samuel A. Jacobs

139 papers receiving 2.7k citations

Peers

Countries citing papers authored by Samuel A. Jacobs

Since Specialization

Citations

This map shows the geographic impact of Samuel A. Jacobs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel A. Jacobs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel A. Jacobs more than expected).

Fields of papers citing papers by Samuel A. Jacobs

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel A. Jacobs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel A. Jacobs. The network helps show where Samuel A. Jacobs may publish in the future.

Co-authors

The 25 scholars most cited alongside Samuel A. Jacobs, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Samuel A. Jacobs Line = papers co-authored together Samuel A. Jacobs links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Effect of cross-platform gene-expression, computational methods on breast cancer subtyping in PALOMA-2 and PALLET studies npj Breast Cancer ·英樹杠, Mothaffar F. Rimawi, Stephen Johnston, Samuel A. Jacobs, Judith M. Bliss, Katherine L. Pogue–Geile, Lucy Kilburn, Zhou Zhu, Eugene F. Schuster, Hui Xiao, M.S. Drozdetskaya, Shibing Deng, Dongrui R. Lu, Eric Gauthier, Jennifer Tursi, Dennis J. Slamon, Hope S. Rugo, Richard S. Finn, Yuan Liu	2024	0
2	Prospective Correlation of Magnetic Resonance Tumor Regression Grade With Pathologic Outcomes in Total Neoadjuvant Therapy for Rectal Adenocarcinoma Journal of Clinical Oncology ·William A. Hall, Jiahe Li, Y. Nancy You, Marc J. Gollub, Joseph R. Grajo, Mark Rosen, Ahmad Jazuly Nabil, Greg Yothers, Jennifer A. Dorth, Osama E. Rahma, Marcia M. Russell, Howard M. Gross, Samuel A. Jacobs, Bryan A. Faller, سلطان بن قاسم أحمد عطیف, Tareq Al Baghdadi, Michael G. Haddock, Richard K. Valicenti, Theodore S. Hong, Thomas J. George	2023	15
3	Definitive results of a phase III adjuvant trial comparing six cycles of FEC-100 to four cycles of AC in women with operable node-negative breast cancer: the NSABP B-36 trial (NRG Oncology) Breast Cancer Research and Treatment ·Charles E. Geyer, Hanna Bandos, Priya Rastogi, Samuel A. Jacobs, André Robidoux, Louis Fehrenbacher, Patrick J. Ward, Jonathan Polikoff, Adam Brufsky, Louise Provencher, Alexander Paterson, John Hamm, Theodore H. Asch, Luis Báez-Díaz, Thomas B. Julian, Sandra M. Swain, Eleftherios P. Mamounas, Norman Wolmark	2022	4
4	Molecular subtypes of colorectal cancer in pre-clinical models show differential response to targeted therapies: Treatment implications beyond KRAS mutations PLoS ONE ·Rekha Pal, Ning Wei, Nan Song, Shaoyu Wu, Rim S. Kim, Ying Wang, Patrick G. Gavin, Peter C. Lucas, Ashok Srinivasan, Carmen J. Allegra, Samuel A. Jacobs, Soonmyung Paik, John C. Schmitz, Katherine L. Pogue–Geile	2018	8
5	Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9 Breast Cancer Research and Treatment ·Jame Abraham, André Robidoux, Antoinette R. Tan, Steven Limentani, Keren Sturtz, Jay H. Davidson, Joelson Gonçalves de Carvalho, Marc Buyse, Norman Wolmark, Samuel A. Jacobs	2015	19
6	HER2 Activating Mutations Are Targets for Colorectal Cancer Treatment Cancer Discovery ·Shyam M. Kavuri, Naveen Jain, Francesco Galimi, Francesca Cottino, Simonetta M. Leto, Giorgia Migliardi, Adam C. Searleman, Wei Shen, John Monsey, Livio Trusolino, Samuel A. Jacobs, Andrea Bertotti, Ron Bose	2015	218
7	Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report Leukemia & lymphoma ·Thomas E. Witzig, Paul A. S. Fishkin, Leo I. Gordon, Stephanie A. Gregory, Samuel A. Jacobs, Roger M. Macklis, Peter McLaughlin, Oliver W. Press, Andrew D. Zelenetz	2011	25
8	In situ mantle cell lymphoma: clinical implications of an incidental finding with indolent clinical behavior Haematologica ·Zinhle Thobeka Fakude, Luz F. Sua, 雄治加賀, Stefania Pittaluga, Cristina Royo, Joo Y. Song, Rachel L. Sargent, Blanca Espinet, Fina Climent, Samuel A. Jacobs, Jan Delabie, Kikkeri N. Naresh, Adam Bagg, Pierre Brousset, Roger A. Warnke, Sérgio Serrano, Nancy L. Harris, Steven H. Swerdlow, Elaine S. Jaffe, Elı́as Campo	2011	105
9	Structure-based engineering of a monoclonal antibody for improved solubility Protein Engineering Design and Selection ·Sheng‐Jiun Wu, Jinquan Luo, Karyn T. O’Neil, Jing X. Kang, Eilyn R. Lacy, Gabriela Canziani, Alison Baker, Mou‐Tuan Huang, Qing Tang, T. Shantha Raju, Samuel A. Jacobs, A. Teplyakov, Gary L. Gilliland, Yiqing Feng	2010	148
10	Radioisotopic Localization of 90Yttrium–Ibritumomab Tiuxetan in Patients with CD20+ Non-Hodgkin’s Lymphoma Molecular Imaging and Biology ·Samuel A. Jacobs, Anthony M. Harrison, Steven H. Swerdlow, Kenneth A. Foon, Norbert Avril, N. Vidnovic, Judith M. Joyce, Manuel Ignacio Nieblas López, Kenneth S. McCarty	2008	9
11	Spontaneous CD4+ T Cell Responses against TRAG-3 in Patients with Melanoma and Breast Cancers The Journal of Immunology ·Bratislav Janjic, J. Linek, Xiaofei Wang, Julien Fourcade, Christine Almunia, Pavol Kudela, Adam Brufsky, Samuel A. Jacobs, David Friedland, Ronald G. Stoller, Daniel Gillet, Ronald B. Herberman, John M. Kirkwood, Bernard Maillère, Hassane M. Zarour	2006	15
12	Pemetrexed/Oxaliplatin for First-Line Treatment of Patients with Advanced Colorectal Cancer: A Phase II Trial of the National Surgical Adjuvant Breast and Bowel Project Foundation Research Program Clinical Colorectal Cancer ·James N. Atkins, Samuel A. Jacobs, H. Samuel Wieand, Roy E. Smith, William J. John, Linda H. Colangelo, Victor G. Vogel, J. Philip Kuebler, Terrence P. Cescon, Bárbara Miller, Charles E. Geyer, Norman Wolmark	2005	19
13	Physician-patient relationship in the intensive care unit: Erosion of the sacred trust? Critical Care Medicine ·Elizabeth Chaitin, Ronald A. Stiller, Samuel A. Jacobs, Antti Pelttari, Pedro Queirós, Joel M. Weinberg	2003	25
14	Indolent mantle cell lymphoma with nodal involvement and mutated immunoglobulin heavy chain genes Human Pathology ·Laurentia Nodit, David W. Bahler, Samuel A. Jacobs, Joseph Locker, Steven H. Swerdlow	2003	72
15	A Phase II Study of Topotecan in Non-Hodgkin's Lymphoma: An Ohio State University Phase II Research Consortium Study Cancer Investigation ·Eric H. Kraut, Stanley P. Balcerzak, Donn C. Young, Mellar P. Davis, Samuel A. Jacobs	2002	8
16	The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. The Journal of Experimental Medicine ·Matthew Peters, Samuel A. Jacobs, Marc Ehlers, Petra Vollmer, Jürgen Müllberg, Eckhard Wolf, Г. Брем, K. H. Meyer zum Büschenfelde, Stefan Rose‐John	1996	246
17	ASR volume 34 issue 2 Cover and Front matter African Studies Review ·Carol Thompson, 侯瑞芬, Samuel A. Jacobs, Rosemary C. Hynes, Ladipo Adamolekun, Kristin Mann, V. Y. Mudimbé, Maxwell Owusu, (unknown), (unknown)	1991	1
18	1,3-Bis(2-chloroethyl)-1-nitrosourea (BCNU)-induced Pulmonary Fibrosis Neurosurgery ·Robert G. Selker, Samuel A. Jacobs, S. CHANNON, Nadia Nawang Nastiti, Edwin R. Fisher, Zafer İLBARS, Yuji Kitamura	1980	40
19	Dose-dependent metabolism of methotrexate in man and rhesus monkeys. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Samuel A. Jacobs, Ronald G. Stoller, B A Chabner, D G Johns	1977	45
20	Candida arthritis treated with amphotericin B The Journal of Pediatrics ·David G. Poplack, Samuel A. Jacobs	1975	20

About Samuel A. Jacobs

Samuel A. Jacobs is a scholar working on Oncology, Pathology and Forensic Medicine, Cancer Research, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging, having authored 143 papers that have together received 2.9k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (56 papers), Cancer Treatment and Pharmacology (30 papers), Lymphoma Diagnosis and Treatment (29 papers), Cancer Genomics and Diagnostics (23 papers), Genetic factors in colorectal cancer (21 papers), HER2/EGFR in Cancer Research (18 papers), Lung Cancer Treatments and Mutations (18 papers) and Colorectal Cancer Surgical Treatments (14 papers). The work is most often cited by research in Oncology (1.4k citations), Pathology and Forensic Medicine (753 citations), Genetics (356 citations), Hematology (279 citations) and Cancer Research (329 citations). Samuel A. Jacobs has collaborated with scholars based in United States, Canada and Belgium. Frequent co-authors include Ronald G. Stoller, Bruce A. Chabner, D G Johns, Kenneth R. Hande, Steven A. Rosenberg, Norman Wolmark, Steven H. Swerdlow, K. H. Meyer zum Büschenfelde, Stefan Rose‐John and Г. Брем. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research, Blood, Clinical Breast Cancer and Cancer Chemotherapy and Pharmacology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact